Ownership and insider activity for BioNTech SE (BNTX): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
BioNTech SE, a biotechnology firm, specializes in the creation and marketing of immune-based treatments for malignancies and various infectious diseases. A significant part of its oncology pipeline includes the FixVac cancer vaccine program, which features several candidates in different phases of clinical development: BNT111 is in Phase 2 for advanced melanoma. BNT112 has reached Phase 1/2a for prostate cancer.
Price
| Price | $87.99 (closing price, October 28, 2026) |
| Market Cap | $22.1B |
| Exchange | NASDAQ |
| Country | DE |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-10-08 | Sahin Ugur | S-Sale | 27,000 | $2.5M |
| 2026-10-09 | Sahin Ugur | S-Sale | 36,209 | $3.5M |
| 2026-10-07 | Sahin Ugur | S-Sale | 24,000 | $2.3M |
| 2026-10-05 | Sahin Ugur | S-Sale | 72,000 | $7.0M |
| 2026-10-06 | Sahin Ugur | S-Sale | 21,000 | $2.0M |
| 2026-10-01 | Sahin Ugur | S-Sale | 17,000 | $1.7M |
| 2026-10-02 | Sahin Ugur | S-Sale | 17,000 | $1.6M |
| 2026-09-29 | Sahin Ugur | S-Sale | 34,000 | $3.3M |
| 2026-09-30 | Sahin Ugur | S-Sale | 32,000 | $3.1M |
| 2026-09-25 | Sahin Ugur | S-Sale | 27,000 | $2.7M |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 303.7M EUR | 172.1M EUR | 411.5M EUR | 519.1M EUR | 1.21B EUR | 1.69B EUR | 13.88B EUR | 11.66B EUR | 9.76B EUR | 7.67B EUR |
| Short-term Investments | 1.5M EUR | 246,000 EUR | 336,000 EUR | 1.7M EUR | 137.2M EUR | 381.6M EUR | 189.4M EUR | 4.89B EUR | 7.02B EUR | 7.16B EUR |
| Receivables | 6.0M EUR | 4.6M EUR | 28.4M EUR | 11.9M EUR | 165.5M EUR | 12.38B EUR | 7.15B EUR | 2.34B EUR | 1.52B EUR | 984.5M EUR |
| Inventory | 3.3M EUR | 3.9M EUR | 5.8M EUR | 12.1M EUR | 64.1M EUR | 502.5M EUR | 439.6M EUR | 357.7M EUR | 283.3M EUR | 110.7M EUR |
| Total Current Assets | 318.1M EUR | 189.6M EUR | 449.0M EUR | 560.2M EUR | 1.67B EUR | 15.07B EUR | 21.92B EUR | 19.53B EUR | 18.80B EUR | 16.14B EUR |
| Property, Plant & Equipment | 60.5M EUR | 101.5M EUR | 116.0M EUR | 148.1M EUR | 326.0M EUR | 520.4M EUR | 821.1M EUR | 971.6M EUR | 1.18B EUR | 1.29B EUR |
| Goodwill | 534,000 EUR | 534,000 EUR | 534,000 EUR | 3.0M EUR | 53.7M EUR | 57.8M EUR | 61.2M EUR | 362.5M EUR | 380.6M EUR | 367.7M EUR |
| Intangible Assets | 10.7M EUR | 83.0M EUR | 87.5M EUR | 84.1M EUR | 103.8M EUR | 144.6M EUR | 158.5M EUR | 804.1M EUR | 790.4M EUR | 1.61B EUR |
| Total Assets | 390.0M EUR | 374.7M EUR | 653.0M EUR | 797.6M EUR | 2.32B EUR | 15.83B EUR | 23.28B EUR | 23.01B EUR | 22.53B EUR | 21.98B EUR |
| Accounts Payable | 6.2M EUR | 52.5M EUR | 41.7M EUR | 20.5M EUR | 102.3M EUR | 160.0M EUR | 204.1M EUR | 354.0M EUR | 426.7M EUR | 534.7M EUR |
| Short-term Debt | 0 | 0 | 0 | 1.8M EUR | 3.0M EUR | 129.9M EUR | 36.0M EUR | 28.1M EUR | 39.5M EUR | 52.2M EUR |
| Total Current Liabilities | 56.6M EUR | 158.5M EUR | 126.1M EUR | 138.1M EUR | 606.0M EUR | 3.48B EUR | 2.95B EUR | 2.07B EUR | 2.52B EUR | 2.14B EUR |
| Long-term Debt | 0 | 0 | 0 | 14.8M EUR | 152.9M EUR | 171.6M EUR | 176.2M EUR | 191.0M EUR | 214.7M EUR | 29.9M EUR |
| Total Liabilities | 358.1M EUR | 422.9M EUR | 386.0M EUR | 304.2M EUR | 946.8M EUR | 3.94B EUR | 3.22B EUR | 2.76B EUR | 3.12B EUR | 2.76B EUR |
| Retained Earnings | -112.1M EUR | -197.8M EUR | -245.8M EUR | -424.8M EUR | -409.6M EUR | 9.88B EUR | 18.83B EUR | 19.76B EUR | 19.10B EUR | 17.95B EUR |
| Total Equity | 30.5M EUR | -49.3M EUR | 266.2M EUR | 493.5M EUR | 1.37B EUR | 11.89B EUR | 20.06B EUR | 20.25B EUR | 19.41B EUR | 19.22B EUR |
| Total Debt | 26.7M EUR | 50.3M EUR | 54.2M EUR | 74.2M EUR | 240.1M EUR | 301.5M EUR | 212.2M EUR | 219.1M EUR | 254.2M EUR | 267.3M EUR |
| Net Debt | -278.5M EUR | -122.0M EUR | -357.6M EUR | -446.6M EUR | -1.11B EUR | -1.77B EUR | -13.85B EUR | -16.33B EUR | -16.53B EUR | -14.57B EUR |
| Working Capital | 261.5M EUR | 31.1M EUR | 322.8M EUR | 422.0M EUR | 1.06B EUR | 11.59B EUR | 18.97B EUR | 17.46B EUR | 16.28B EUR | 14.00B EUR |
Financial Health
| Debt / Equity | 0.02 |
| Current Ratio | 7.85 |
| Piotroski F-Score | 5 |
| Altman Z-Score | 6.19 |
Profitability
| Return on Equity | -9.16% |
| Return on Invested Capital | -9.25% |
| Return on Assets | -8.34% |
| Gross Margin | 68.95% |
| Operating Margin | -64.63% |
| Net Margin | -64.25% |
Related companies: INCY · GMAB · IBRX · TGTX · IOVA · XNCR
Explore sector: Healthcare · Biotechnology
More sections of BNTX: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method today · Companies that pass the Lynch method today · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks